<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22932" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Prevention of Opportunistic Infections in HIV/AIDS</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sadiq</surname>
            <given-names>Usama</given-names>
          </name>
          <aff>Abington Memorial Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shrestha</surname>
            <given-names>Utsav</given-names>
          </name>
          <aff>University of Pittsburgh Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Guzman</surname>
            <given-names>Nilmarie</given-names>
          </name>
          <aff>Orange Park Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Usama Sadiq declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Utsav Shrestha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nilmarie Guzman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22932.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>HIV/ AIDS patients with a low CD4 count have decreased humoral and cellular immunity, predisposing them to opportunistic infections. These diseases are associated with significant morbidity and mortality in patients with HIV/AIDS. This activity will highlight the prevalence and risk factors of common opportunistic infections in HIV/AIDS patients. It will proved a concise review for an interprofessional team of physicians, specialists, and nurses in the current guidelines for prophylactic antibiotic use and vaccinations against common opportunistic infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the pathophysiology and risk factors of opportunistic infections.</p></list-item><list-item><p>Describe the role of antiviral therapy, vaccinations and immunizations in the prevention of opportunistic infections.</p></list-item><list-item><p>Identify the development of immune reconstitution syndrome after initiation of HAART.</p></list-item><list-item><p>Outline the common opportunistic infections in HIV patients, risk factors for exposure and prophylactic antibiotics.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22932&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22932">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22932.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Opportunistic infections (OI) are a significant&#x000a0;cause of morbidity and mortality in patients with HIV/AIDS.&#x000a0;Although the incidence of OI has reduced since the introduction of highly active antiretroviral therapy (ART) in 1995, it continues to add to the burden of HIV-related hospitalizations and deaths in patients. This is particularly true in patients who have not received HAART therapy or who have been non-compliant to&#x000a0;it.<xref ref-type="bibr" rid="article-22932.r1">[1]</xref><xref ref-type="bibr" rid="article-22932.r2">[2]</xref> These&#x000a0;infections generally lack the virulence and pathogenicity to cause disease in immunocompetent hosts and are hence an uncommon phenomenon.<xref ref-type="bibr" rid="article-22932.r3">[3]</xref>However, due to the immunodeficiency, the risk of OI in HIV/AIDS is substantially increased, particularly in the absence of ART and antimicrobial prophylaxis.&#x000a0;</p>
        <p>There is&#x000a0;a progressive decrease in CD4+ counts in HIV/AIDS when left untreated. CD4+ cells play an important role in&#x000a0;mounting an immune response against infections. These cells release cytokines that&#x000a0;lead to the activation of antigen-presenting cells, phagocytic cells, natural killer cells, and cytotoxic T cells.&#x000a0; They also support the conversion of B-lymphocytes into long-lived plasma cells and memory B cells. A&#x000a0;decrease in CD4+ T cell count thus leads to a decline in both humoral and cell-mediated immunity. Ultimately&#x000a0;it predisposes patients to&#x000a0;a higher risk of contracting opportunistic diseases due to viruses, bacteria, fungi, and protozoa.<xref ref-type="bibr" rid="article-22932.r4">[4]</xref><xref ref-type="bibr" rid="article-22932.r5">[5]</xref><xref ref-type="bibr" rid="article-22932.r6">[6]</xref><xref ref-type="bibr" rid="article-22932.r7">[7]</xref><xref ref-type="bibr" rid="article-22932.r8">[8]</xref>&#x000a0;As the dogma of medicine is "Prevention is better than cure", preventing opportunistic infections in HIV/AIDS patients is paramount to seeing a decrease in both disease burden and associated mortality. In this review article, we discuss the methods of preventing opportunistic infections in HIV/AIDS patients.&#x000a0;</p>
      </sec>
      <sec id="article-22932.s3" sec-type="Function">
        <title>Function</title>
        <p>
<bold>Strategies to prevent opportunistic infections in HIV/AIDS:</bold>
</p>
        <p>Prevention of opportunistic infections in HIV/AIDS&#x000a0;involves a multidisciplinary approach that includes primary care physicians, infectious disease agents, and social workers for support. Early initiation of HAART remains the most efficient method for preventing OI.<xref ref-type="bibr" rid="article-22932.r9">[9]</xref><xref ref-type="bibr" rid="article-22932.r10">[10]</xref><xref ref-type="bibr" rid="article-22932.r11">[11]</xref>Additional methods include the felicitous application of several strategies including vaccinations, screenings for co-infections, avoidance of exposures, patient education, and antibiotic prophylaxis.&#x000a0;</p>
        <p><bold>1. Screening for co-infections:</bold>&#x000a0;&#x000a0;</p>
        <p>It is highly recommended that patients with a newly diagnosed HIV infection be screened for the following infections, commonly found concurrently with HIV infection:</p>
        <table-wrap id="article-22932.table0" position="float" orientation="portrait">
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Disease</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Screening method</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Screening frequency</bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Screening for Sexually transmitted diseases</bold>:<xref ref-type="bibr" rid="article-22932.r12">[12]</xref><xref ref-type="bibr" rid="article-22932.r13">[13]</xref><xref ref-type="bibr" rid="article-22932.r14">[14]</xref><xref ref-type="bibr" rid="article-22932.r15">[15]</xref></p>
<list list-type="bullet"><list-item><p>Syphilis&#x000a0;</p></list-item><list-item><p>Chlamydia and gonorrhea&#x000a0;</p></list-item><list-item><p>Trichomonas (screening in women only)&#x000a0;</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0; &#x000a0; RPR or VDRL test for syphilis.</p></list-item><list-item><p>&#x000a0; &#x000a0; NAAT for chlamydia and gonorrhea, ideally from all urethra, rectum, and oral samples.</p></list-item><list-item><p>&#x000a0;Wet mount for Trichomonas infection following a per-vaginal exam.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>At&#x000a0;the time of the initial diagnosis of HIV and then annually. If patient high-risk sexual behavior (such as men having sex with men or promiscuous behavior), it is recommended that they get tested more frequently.&#x000a0;</p></list-item></list>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Latent Tuberculosis</bold><xref ref-type="bibr" rid="article-22932.r16">[16]</xref><xref ref-type="bibr" rid="article-22932.r17">[17]</xref></p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Tuberculin skin test or Interferon-gamma test.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>At the time of diagnosis or initiation of ART. Then annually if there is a history of prior exposure to tuberculosis or ongoing risk of exposure (e.g. homelessness or incarcerated).</p></list-item></list>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Hepatitis A and</bold></p>
<p><bold>Hepatitis B</bold><xref ref-type="bibr" rid="article-22932.r18">[18]</xref><xref ref-type="bibr" rid="article-22932.r19">[19]</xref><xref ref-type="bibr" rid="article-22932.r20">[20]</xref></p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;&#x000a0;Hepatitis A IgM, IgG antibody</p></list-item><list-item><p>Hepatitis B surface antigen Ab (HBsAg), IgG HBsAg, IgM HBsAg, Hepatitis B core antigen.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>At the time of diagnosis or initiation of ART. And after vaccination to evaluate for an immunogenic response.</p></list-item></list>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Hepatitis C</bold><xref ref-type="bibr" rid="article-22932.r21">[21]</xref><xref ref-type="bibr" rid="article-22932.r22">[22]</xref><xref ref-type="bibr" rid="article-22932.r23">[23]</xref><xref ref-type="bibr" rid="article-22932.r24">[24]</xref></p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;Hepatitis C antibody with reflex DNA PCR is positive.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>At the time of diagnosis or initiation of ART. Then, annually for high-risk patients (e.g. Intravenous drug users).</p></list-item></list>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Coccidioidomycosis</bold><xref ref-type="bibr" rid="article-22932.r25">[25]</xref><xref ref-type="bibr" rid="article-22932.r26">[26]</xref></p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;IgG and IgM against coccidioides spp.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Annual screening is recommended in certain endemic states, such as California and Arizona.</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>&#x000a0;2. Role of antimicrobial prophylaxis:</bold>
</p>
        <p>Antimicrobial prophylaxis, in addition to ART, is indicated in patients with severe immunosuppression and resultant increased risk of opportunistic infections. Low CD4 + cell count acts as a marker of the severity of an immunosuppressed state.&#x000a0;<xref ref-type="bibr" rid="article-22932.r27">[27]</xref><xref ref-type="bibr" rid="article-22932.r28">[28]</xref><xref ref-type="bibr" rid="article-22932.r29">[29]</xref></p>
        <p>Antimicrobial prophylaxis can be safely discontinued once CD4+ cell count is &#x0003e; 200&#x000a0;cells/microL for more than six months after the initiation of ART. The following table shows the common organisms that cause opportunistic disease in HIV/AIDS patients below certain thresholds of CD4 + cell count.<xref ref-type="bibr" rid="article-22932.r30">[30]</xref><xref ref-type="bibr" rid="article-22932.r31">[31]</xref><xref ref-type="bibr" rid="article-22932.r32">[32]</xref></p>
        <table-wrap id="article-22932.table1" position="float" orientation="portrait">
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0; &#x000a0;Organism&#x000a0; &#x000a0;&#x000a0;</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Disease</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;CD4 count at risk</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;Prophylaxis</bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Mycobacterium tuberculin</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Pulmonary or extrapulmonary TB</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Any count, if the screening test is positive or patients have a prior history of active TB.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>If the screening test is positive, the first step is to rule out an active disease with a chest X-ray. If negative, start Isoniazid for 9 months.</p></list-item></list>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">Coccidioides</italic> sp.</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Coccidioidomycosis</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x0003c; 250 cells/microL</p></list-item><list-item><p>And from endemic regions of southwestern United States</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Fluconazole for patients with positive serological tests.</p></list-item></list>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Pneumocystis <italic toggle="yes">jirovecii</italic></p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Pneumocystis pneumonia</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x0003c; 200 cells/microL</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Trimethoprim-Sulfamethoxazole.</p></list-item><list-item><p>Alternate agents: Dapsone, atovaquone, or aerosolized pentamidine.</p></list-item></list>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Toxoplasma</p>
<p>gondi</p>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Toxoplasmosis</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x0003c; 100 cells/microL&#x000a0;</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Trimethoprim-Sulfamethoxazole.</p></list-item><list-item><p>Alternate agents:</p></list-item></list>
<p>&#x000a0; &#x000a0; &#x000a0; &#x000a0;-&#x000a0; Dapsone + pyrimethamine + leucovorin&#x000a0;</p>
<p>&#x000a0; &#x000a0; &#x000a0; &#x000a0;-&#x000a0; Atovaquone + pyrimethamine.</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>There is little or no evidence to suggest a clinical benefit of starting antimicrobial prophylaxis against the following organisms:</p>
        <p>1. Histoplasma capsulated</p>
        <p>2. Mycobacterium avium complex (MAC)</p>
        <p>3. Bartonella spp</p>
        <p>4. Cytomegalovirus (CMV)</p>
        <p>5. Cryptosporidium&#x000a0;</p>
        <p>6. Candida spp.&#x000a0;</p>
        <p>These organisms have a low incidence in HIV/AIDS patients and there is potential for significant drug interactions with HAART therapy if prophylaxis is started concomitantly.&#x000a0; Thus, the timely initiation of HAART and subsequent improvement in CD4 + cell count alone is thought to provide&#x000a0;adequate prevention against disease.&#x000a0;</p>
        <p><bold>3. Role of vaccinations:</bold>&#x000a0;</p>
        <p>&#x000a0;The therapeutic efficacy or immunogenic potential of vaccines has not been fully established in HIV/AIDS patients. The&#x000a0;decline in immune response in HIV/AIDS patients with low CD4+ cell counts poses a major hurdle in obtaining a robust and long-lasting protective benefit against disease.<xref ref-type="bibr" rid="article-22932.r33">[33]</xref><xref ref-type="bibr" rid="article-22932.r34">[34]</xref><xref ref-type="bibr" rid="article-22932.r35">[35]</xref>Despite these limitations, vaccinations are strongly encouraged in this population given the potential benefit in alleviating the severity and mortality from a vaccine-preventable disease. In general, inactivated vaccines are generally preferred over live vaccines due to the potential risk of vaccine-related illness. If there is any doubt regarding immunogenicity or subsequent testing does not show an appropriate antibody response, it is revaccination is recommended once CD4+ cell count &#x0003e;&#x000a0;200 cells/microL has been achieved.&#x000a0;<xref ref-type="bibr" rid="article-22932.r30">[30]</xref><xref ref-type="bibr" rid="article-22932.r36">[36]</xref><xref ref-type="bibr" rid="article-22932.r37">[37]</xref></p>
        <p>The following vaccines are routinely recommended in HIV/AIDS patients:</p>
        <list list-type="order">
          <list-item>
            <p>Seasonal influenza vaccine inactivated form administered annually.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tetanus, Diptheria, acellular pertussis (TdaP): Recommended in all patients 11 years or older&#x000a0;who have not yet received it yet followed by&#x000a0;Tetanus, Diptheria (Td) booster dose every 10 years.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Human papillomavirus (HPV): Generally administered during adolescent years of 11 -12 years, but in HIV patients, it is recommended up to 26 years of age. Administration of this vaccine even beyond 26 years of age has been recommended in patients with high-risk sexual behavior.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pneumococcal vaccine: Patients older than 2 years old are recommended to get a Pneumococcal conjugate vaccine (PCV13 or Prevnar) with any CD4+ cell count followed by&#x000a0;Pneumococcal polysaccharide vaccine&#x000a0; (PPSV23 or Pneumovax) after at least 8 weeks. It is recommended that this booster be given after the CD4+ cell count improves to &#x0003e;200 cells/microL. A further dose of&#x000a0;PPSV23 is recommended after 5 years of the first PPSV23 administration.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatitis A and Hepatitis B vaccine: Administered to patients who are found to be non-immune during routine screening.&#x000a0; It is recommended to check for an appropriate antibody response after one month of vaccine administration. If a poor response is seen, the administration of a vaccine after CD4+ cell count improves to&#x000a0;&#x0003e;200 cells/microL is recommended.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Meningococcal vaccinations: Administration of meningococcal conjugate vaccine with serogroups A, C, W, Y is recommended in patients above the age of 2 months. In addition to this, the serogroup B vaccine is recommended in patients with asplenia, complement deficiency, and during meningococcal outbreaks involving serogroup B.&#x000a0;</p>
          </list-item>
        </list>
        <p>Certain vaccines are recommended when patients fulfill certain indications, such as:<xref ref-type="bibr" rid="article-22932.r31">[31]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Haemophilus influenza b: Only indicated in children aged 5 to 8 years of age or in adults at risk of disseminated Hemophilus infections such as asplenia or complement deficiency.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Measles, Mumps, Rubella: For patients without severely immunocompromised state (CD4 count &#x0003c; 200cells/microL in adults or less than 15 % in children less than 5 years old), two doses of MMR vaccine 28 days apart is recommended if they do not have any evidence of previous immunity. For someone with a clear history of prior immunization, laboratory finding of an immune response, or birth before 1957 AD, vaccinations are not necessary.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Varicella vaccine: Recommended in patients born after 1979 and who do not have anti-varicella IgG or clearly documented history of receiving two doses of varicella vaccine when their CD4 count was &#x0003e;200&#x000a0;cells/microL.</p>
          </list-item>
          <list-item>
            <p>Zoster vaccine: HIV patients 50 years or older should receive two doses of non-live recombinant Zoster vaccine (RZV), intramuscular, 8 weeks apart as per the US department of health and human services.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>4. Minimizing the risk of exposure:</bold>
</p>
        <p>&#x000a0;Opportunistic infections can be contracted by immunocompromised hosts in several ways:</p>
        <list list-type="bullet">
          <list-item>
            <p>Presence of high-risk environments to contract the disease (patients who contract Tuberculosis due to close proximity to other infected individuals e.g in prison or homelessness)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Presence of high-risk&#x000a0;practices (e.g. Hepatitis B, Hepatitis C in patients using intravenous drugs, men who have sex with men, or people with multiple sexual partners).</p>
          </list-item>
          <list-item>
            <p>Close proximity to certain vectors, who are carriers of the disease can also increase the risk of exposure and result in disease. For example, Crytococccas can be transmitted by pigeons and Toxoplasmosis from cat droppings.&#x000a0;</p>
          </list-item>
        </list>
        <p>It is understandable that certain risks of exposure such as being incarcerated or homeless might be difficult to remedy. However, patients should be counseled regarding avoidable exposures such as pets (cats, birds), high-risk sexual practice, and prevention of sexually transmitted diseases with the use of barrier contraceptives.&#x000a0;</p>
      </sec>
      <sec id="article-22932.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Immune Reconstitution Syndrome (IRIS)</bold>
</p>
        <p>Immune reconstitution inflammatory syndrome is a clinical phenomenon that occurs after the initiation of antiretroviral therapy. It represents a paradoxical worsening of preexisting infectious processes following improvement in immune response and a subsequent state of elevated inflammatory response.&#x000a0; The preexisting infections can be subclinical (e.g. Toxoplasmosis) or previously treated infections (Tuberculosis). The clinical presentation depends on the location and severity of inflammation.<xref ref-type="bibr" rid="article-22932.r38">[38]</xref><xref ref-type="bibr" rid="article-22932.r39">[39]</xref><xref ref-type="bibr" rid="article-22932.r40">[40]</xref><xref ref-type="bibr" rid="article-22932.r41">[41]</xref><xref ref-type="bibr" rid="article-22932.r42">[42]</xref></p>
        <p>IRIS has been found to occur in up to 30 % of HIV/AIDS patients receiving ART. Low CD4 cell counts or high HIV RNA load at the time of initiation of ART has been thought to be important risk factors for IRIS.<xref ref-type="bibr" rid="article-22932.r43">[43]</xref><xref ref-type="bibr" rid="article-22932.r44">[44]</xref><xref ref-type="bibr" rid="article-22932.r45">[45]</xref>&#x000a0;</p>
        <p>There are no universally accepted diagnostic criteria for IRIS, but the&#x000a0;presence of the following features is thought to be highly suggestive:<xref ref-type="bibr" rid="article-22932.r46">[46]</xref><xref ref-type="bibr" rid="article-22932.r47">[47]</xref><xref ref-type="bibr" rid="article-22932.r48">[48]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Presence of AIDS with a low pretreatment CD4 count (often less than 100&#x000a0;cells/mm3). However,&#x000a0;IRIS secondary to preexisting M. tuberculosis infection may occur in individuals with CD4 counts greater than 200&#x000a0;cells/mm3.</p>
          </list-item>
          <list-item>
            <p>Patients should have no evidence of resistance to ART or lowered therapeutic efficacy due to drug interactions.</p>
          </list-item>
          <list-item>
            <p>Temporal association initiation of ART and the onset of illness. There must be evidence of immunological response to antiretroviral therapy with improving CD4+ cell count.</p>
          </list-item>
          <list-item>
            <p>Presence of clinical manifestations consistent with an inflammatory condition, such as:</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>CMV associated IRIS:&#x000a0;painless floaters, blurred vision, ocular pain.</p>
          </list-item>
          <list-item>
            <p>MAC associated IRIS: Fever and tender lymph node enlargement.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cryptococcal infection-associated IRIS: fever, neck rigidity</p>
          </list-item>
        </list>
        <p>&#x000a0; &#x000a0; &#x000a0; 5. Other causes of clinical deterioration such as drug allergies (e.g. with abacavir), new opportunistic infections must be considered and ruled out.&#x000a0;</p>
        <p>The most common pathogens&#x000a0;that are commonly associated with IRIS&#x000a0;are&#x000a0;<italic toggle="yes">Mycobacterium tuberculosis,&#x000a0;</italic><italic toggle="yes">Mycobacterium avium </italic>complex,&#x000a0;Cytomegalovirus,&#x000a0;<italic toggle="yes">Cryptococcus neoforman,&#x000a0;</italic><italic toggle="yes">Pneumocystis jirovecii,&#x000a0;</italic>Herpes simplex virus, Hepatitis B virus, Human herpesvirus 8.<xref ref-type="bibr" rid="article-22932.r39">[39]</xref><xref ref-type="bibr" rid="article-22932.r49">[49]</xref>A detailed explanation of pathophysiology and management of IRIS is beyond the scope of this review article. However, a crucial learning point regarding the management of IRIS is that it is directed towards the management of underlying opportunistic infection, and at no point should ART be stopped.&#x000a0;</p>
      </sec>
      <sec id="article-22932.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The timely introduction of ART to improved CD4+ counts is the most efficient method of minimizing the risk of opportunistic infections. The use of ART can however lead to IRIS due to inflammatory response once improvement of CD4+ cell count is seen and immune response has been achieved. The presentation of IRIS can be nonspecific and depends on the type of opportunistic infection, location, and severity of inflammatory response. Due to its nonspecific presentation, it can be hard to differentiate it from active infections (e.g hospital-acquired pneumonia), a progression of previously diagnosed opportunistic infections, or drug-related side effects. Continuation of ART and symptomatic management is the cornerstone of managing IRIS. The use of steroids is reserved for severe forms of IRIS.&#x000a0;<xref ref-type="bibr" rid="article-22932.r50">[50]</xref><xref ref-type="bibr" rid="article-22932.r51">[51]</xref><xref ref-type="bibr" rid="article-22932.r52">[52]</xref></p>
      </sec>
      <sec id="article-22932.s6" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>HIV patients who are untreated are prone to multiple opportunistic infections due to the progressive lowering of their CD4 + T cells. Because of the high morbidity and mortality of these infections, every attempt should be made that these patients have enough resources for early diagnosis of HIV, timely initiation of ART, regular follow up to ensure medication adherence.</p>
        <p>These patients should be managed by an interprofessional team that includes an infectious disease specialist,&#x000a0;internist, specialist nurse, pharmacists, and social workers. They also need close monitoring with regular lab work to evaluate for improvement of CD4+ cell count, assessment of medication-related side effects, and the emergence of opportunistic infections. Patients with HIV often face social stigma due to their infections. The team must additionally ensure adequate social and financial support, rehabilitation for intravenous drug abusers along with patient education regarding safe sex practices, and avoidance of high-risk behaviors.&#x000a0;</p>
      </sec>
      <sec id="article-22932.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22932&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22932">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22932/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22932">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22932.s8">
        <title>References</title>
        <ref id="article-22932.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmisano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vella</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A brief history of antiretroviral therapy of HIV infection: success and challenges.</article-title>
            <source>Ann Ist Super Sanita</source>
            <year>2011</year>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-8</page-range>
            <pub-id pub-id-type="pmid">21430338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Est&#x000e9;</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cihlar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Current status and challenges of antiretroviral research and therapy.</article-title>
            <source>Antiviral Res</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>85</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-33</page-range>
            <pub-id pub-id-type="pmid">20018390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dropulic</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Lederman</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Overview of Infections in the Immunocompromised Host.</article-title>
            <source>Microbiol Spectr</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">27726779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ai</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Ruan</surname>
                <given-names>QL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>QH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Updates on the risk factors for latent tuberculosis reactivation and their managements.</article-title>
            <source>Emerg Microbes Infect</source>
            <year>2016</year>
            <month>Feb</month>
            <day>03</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>e10</fpage>
            <pub-id pub-id-type="pmid">26839146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vergis</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Mellors</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Natural history of HIV-1 infection.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>809</fpage>
            <page-range>809-25, v-vi</page-range>
            <pub-id pub-id-type="pmid">11144640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alimonti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Fowke</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS.</article-title>
            <source>J Gen Virol</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>84</volume>
            <issue>Pt 7</issue>
            <fpage>1649</fpage>
            <page-range>1649-1661</page-range>
            <pub-id pub-id-type="pmid">12810858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Achhra</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Petoumenos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Relationship between CD4 cell count and serious long-term complications among HIV-positive individuals.</article-title>
            <source>Curr Opin HIV AIDS</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-71</page-range>
            <pub-id pub-id-type="pmid">24275674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ford</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Meintjes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vitoria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chiller</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The evolving role of CD4 cell counts in HIV care.</article-title>
            <source>Curr Opin HIV AIDS</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-128</page-range>
            <pub-id pub-id-type="pmid">28059957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hartogensis</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bacchetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Hatano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Epling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>McCune</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pilcher</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Hecht</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Deeks</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.</article-title>
            <source>J Infect Dis</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>208</volume>
            <issue>8</issue>
            <fpage>1202</fpage>
            <page-range>1202-11</page-range>
            <pub-id pub-id-type="pmid">23852127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Foxall</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Ligeiro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rocha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Godinho-Santos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trombetta</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Early ART in Acute HIV-1 Infection: Impact on the B-Cell Compartment.</article-title>
            <source>Front Cell Infect Microbiol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>347</fpage>
            <pub-id pub-id-type="pmid">32766164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luzuriaga</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tabak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Ziemniak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McManus</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Strain</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Richman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Chun</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Persaud</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment.</article-title>
            <source>J Infect Dis</source>
            <year>2014</year>
            <month>Nov</month>
            <day>15</day>
            <volume>210</volume>
            <issue>10</issue>
            <fpage>1529</fpage>
            <page-range>1529-38</page-range>
            <pub-id pub-id-type="pmid">24850788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quilter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dhanireddy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marrazzo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prevention of Sexually Transmitted Diseases in HIV-Infected Individuals.</article-title>
            <source>Curr HIV/AIDS Rep</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>41</fpage>
            <page-range>41-46</page-range>
            <pub-id pub-id-type="pmid">28374281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cantor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Daeges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <source>Screening for Syphilis in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation [Internet]</source>
            <publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name>
            <publisher-loc>Rockville (MD)</publisher-loc>
            <year>2016</year>
            <month>06</month>
            <pub-id pub-id-type="pmid">27336106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masha</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cools</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Vaneechoutte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crucitti</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title><italic>Trichomonas vaginalis</italic> and HIV infection acquisition: a systematic review and meta-analysis.</article-title>
            <source>Sex Transm Infect</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-42</page-range>
            <pub-id pub-id-type="pmid">30341233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bochner</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Baeten</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rustagi</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Nakku-Joloba</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lingappa</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mugo</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Bukusi</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kapiga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delany-Moretlwe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Celum</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barnabas</surname>
                <given-names>RV</given-names>
              </name>
              <collab>Partners in Prevention HSV/HIV Transmission Study and Partners PrEP Study Teams</collab>
            </person-group>
            <article-title>A cross-sectional analysis of <italic>Trichomonas vaginalis</italic> infection among heterosexual HIV-1 serodiscordant African couples.</article-title>
            <source>Sex Transm Infect</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>93</volume>
            <issue>7</issue>
            <fpage>520</fpage>
            <page-range>520-529</page-range>
            <pub-id pub-id-type="pmid">28377421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ehrlich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baatjies</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dendukuri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dheda</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Evaluating Latent Tuberculosis Infection Test Performance Using Latent Class Analysis in a TB and HIV Endemic Setting.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2019</year>
            <month>Aug</month>
            <day>14</day>
            <volume>16</volume>
            <issue>16</issue>
            <pub-id pub-id-type="pmid">31416206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruchfeld</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Correia-Neves</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000e4;llenius</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis and HIV Coinfection.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2015</year>
            <month>Feb</month>
            <day>26</day>
            <volume>5</volume>
            <issue>7</issue>
            <fpage>a017871</fpage>
            <pub-id pub-id-type="pmid">25722472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulkay</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>[Hepatitis B: screening and treatment].</article-title>
            <source>Rev Med Brux</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>215</fpage>
            <page-range>215-22</page-range>
            <pub-id pub-id-type="pmid">23091924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abara</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Qaseem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schillie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>AM</given-names>
              </name>
              <collab>High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention</collab>
              <name>
                <surname>Abraham</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Centor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>DeLong</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Gantzer</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Horwitch</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Jokela</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JMW</given-names>
              </name>
              <name>
                <surname>Lohr</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention.</article-title>
            <source>Ann Intern Med</source>
            <year>2017</year>
            <month>Dec</month>
            <day>05</day>
            <volume>167</volume>
            <issue>11</issue>
            <fpage>794</fpage>
            <page-range>794-804</page-range>
            <pub-id pub-id-type="pmid">29159414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jooste</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Zyl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adland</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hattingh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brits</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wareing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goedhals</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jeffery</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goulder</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Screening, characterisation and prevention of Hepatitis B virus (HBV) co-infection in HIV-positive children in South Africa.</article-title>
            <source>J Clin Virol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>85</volume>
            <fpage>71</fpage>
            <page-range>71-74</page-range>
            <pub-id pub-id-type="pmid">27838494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Easterbrook</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baggaley</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>HIV and Hepatitis Testing: Global Progress, Challenges, and Future Directions.</article-title>
            <source>AIDS Rev</source>
            <year>2016</year>
            <season>Jan-Mar</season>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-14</page-range>
            <pub-id pub-id-type="pmid">26991825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panneer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lontok</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Branson</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Dan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stekler</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>DeMaria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>HIV and hepatitis C virus infection in the United States: whom and how to test.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Sep</month>
            <day>15</day>
            <volume>59</volume>
            <issue>6</issue>
            <fpage>875</fpage>
            <page-range>875-82</page-range>
            <pub-id pub-id-type="pmid">24867787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kempf</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wise</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Footman</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Araya</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Latham</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stockett</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lanzi</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Universal Screening for HIV and Hepatitis C Infection: A Community-Based Pilot Project.</article-title>
            <source>Am J Prev Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>55</volume>
            <issue>5 Suppl 1</issue>
            <fpage>S112</fpage>
            <page-range>S112-S121</page-range>
            <pub-id pub-id-type="pmid">30670196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terranova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tsoi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Laraque</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Washburn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fuld</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Strengthening Screening for HIV, Hepatitis C, and STIs: An Innovative Partnership Between the Health Department and Community Health Centers in New York City.</article-title>
            <source>Public Health Rep</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>131 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>5</fpage>
            <page-range>5-10</page-range>
            <pub-id pub-id-type="pmid">26862225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McNeil</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ampel</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Opportunistic coccidioidomycosis in patients infected with human immunodeficiency virus: prevention issues and priorities.</article-title>
            <source>Clin Infect Dis</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>21 Suppl 1</volume>
            <fpage>S111</fpage>
            <page-range>S111-3</page-range>
            <pub-id pub-id-type="pmid">8547498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masannat</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Ampel</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy.</article-title>
            <source>Clin Infect Dis</source>
            <year>2010</year>
            <month>Jan</month>
            <day>01</day>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">19995218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brooks</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masur</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated opportunistic infections--going, going, but not gone: the continued need for prevention and treatment guidelines.</article-title>
            <source>Clin Infect Dis</source>
            <year>2009</year>
            <month>Mar</month>
            <day>01</day>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>609</fpage>
            <page-range>609-11</page-range>
            <pub-id pub-id-type="pmid">19191648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ledergerber</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Egger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hirschel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Furrer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Battegay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vernazza</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bernasconi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Opravil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaufmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sudre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Francioli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Telenti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.</article-title>
            <source>JAMA</source>
            <year>1999</year>
            <month>Dec</month>
            <day>15</day>
            <volume>282</volume>
            <issue>23</issue>
            <fpage>2220</fpage>
            <page-range>2220-6</page-range>
            <pub-id pub-id-type="pmid">10605973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palella</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Moorman</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Loveless</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Fuhrer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Satten</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Aschman</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Holmberg</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.</article-title>
            <source>N Engl J Med</source>
            <year>1998</year>
            <month>Mar</month>
            <day>26</day>
            <volume>338</volume>
            <issue>13</issue>
            <fpage>853</fpage>
            <page-range>853-60</page-range>
            <pub-id pub-id-type="pmid">9516219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aberg</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gallant</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ghanem</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Emmanuel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zingman</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Horberg</surname>
                <given-names>MA</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-34</page-range>
            <pub-id pub-id-type="pmid">24235263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Pau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masur</surname>
                <given-names>H</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
              <collab>National Institutes of Health</collab>
              <collab>HIV Medicine Association of the Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2009</year>
            <month>Apr</month>
            <day>10</day>
            <volume>58</volume>
            <issue>RR-4</issue>
            <fpage>1</fpage>
            <page-range>1-207; quiz CE1-4</page-range>
            <pub-id pub-id-type="pmid">19357635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Masur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>KK</given-names>
              </name>
              <collab>USPHS</collab>
              <collab>Infectious Disease Society of America</collab>
            </person-group>
            <article-title>Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2002</year>
            <month>Jun</month>
            <day>14</day>
            <volume>51</volume>
            <issue>RR-8</issue>
            <fpage>1</fpage>
            <page-range>1-52</page-range>
            <pub-id pub-id-type="pmid">12081007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ljungman</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Vaccination of immunocompromised patients.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>18 Suppl 5</volume>
            <fpage>93</fpage>
            <page-range>93-9</page-range>
            <pub-id pub-id-type="pmid">23051059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hechter</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tartof</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Sy</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mercado</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Naleway</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project.</article-title>
            <source>Vaccine</source>
            <year>2019</year>
            <month>May</month>
            <day>31</day>
            <volume>37</volume>
            <issue>25</issue>
            <fpage>3296</fpage>
            <page-range>3296-3302</page-range>
            <pub-id pub-id-type="pmid">31064675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Rukasin</surname>
                <given-names>CRF</given-names>
              </name>
              <name>
                <surname>Beachkofsky</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Immune-mediated adverse reactions to vaccines.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>85</volume>
            <issue>12</issue>
            <fpage>2694</fpage>
            <page-range>2694-2706</page-range>
            <pub-id pub-id-type="pmid">31472022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ljungman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tomblyn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bousvaros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dhanireddy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Keyserling</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>I</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>e44</fpage>
            <page-range>e44-100</page-range>
            <pub-id pub-id-type="pmid">24311479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glesby</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Immunizations during HIV infection.</article-title>
            <source>Curr Opin Infect Dis</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-21</page-range>
            <pub-id pub-id-type="pmid">17033361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wandel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colebunders</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Attia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Furrer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Egger</surname>
                <given-names>M</given-names>
              </name>
              <collab>IeDEA Southern and Central Africa</collab>
            </person-group>
            <article-title>Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-61</page-range>
            <pub-id pub-id-type="pmid">20334848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manzardo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guardo</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Letang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Plana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gatell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Miro</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>751</fpage>
            <page-range>751-67</page-range>
            <pub-id pub-id-type="pmid">25860288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Meintjes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome.</article-title>
            <source>Semin Immunopathol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>185</fpage>
            <page-range>185-98</page-range>
            <pub-id pub-id-type="pmid">26423994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roade Tato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burgos Cibrian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Curran F&#x000e1;bregas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navarro Mercad&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Willekens</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n G&#x000f3;mez</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Ribera Pascuet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Falc&#x000f3; Ferrer</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Immune reconstitution inflammatory syndrome in HIV-infected patients with Pneumocystis jirovecii pneumonia.</article-title>
            <source>Enferm Infecc Microbiol Clin (Engl Ed)</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>621</fpage>
            <page-range>621-626</page-range>
            <pub-id pub-id-type="pmid">29187293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gopal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rapaka</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Kolls</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Immune reconstitution inflammatory syndrome associated with pulmonary pathogens.</article-title>
            <source>Eur Respir Rev</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>143</issue>
            <pub-id pub-id-type="pmid">28049128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratnam</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kandala</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Easterbrook</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort.</article-title>
            <source>Clin Infect Dis</source>
            <year>2006</year>
            <month>Feb</month>
            <day>01</day>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>418</fpage>
            <page-range>418-27</page-range>
            <pub-id pub-id-type="pmid">16392092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manabe</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Sydnor</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Immune reconstitution inflammatory syndrome: risk factors and treatment implications.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2007</year>
            <month>Dec</month>
            <day>01</day>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>456</fpage>
            <page-range>456-62</page-range>
            <pub-id pub-id-type="pmid">18077835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grant</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Komarow</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sereti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pahwa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lederman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Eron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sanne</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Powderly</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suckow</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zolopa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection.</article-title>
            <source>PLoS One</source>
            <year>2010</year>
            <month>Jul</month>
            <day>01</day>
            <volume>5</volume>
            <issue>7</issue>
            <fpage>e11416</fpage>
            <pub-id pub-id-type="pmid">20617176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haddow</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Easterbrook</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Mosam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khanyile</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Parboosing</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moodley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moosa</surname>
                <given-names>MY</given-names>
              </name>
            </person-group>
            <article-title>Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort.</article-title>
            <source>Clin Infect Dis</source>
            <year>2009</year>
            <month>Nov</month>
            <day>01</day>
            <volume>49</volume>
            <issue>9</issue>
            <fpage>1424</fpage>
            <page-range>1424-32</page-range>
            <pub-id pub-id-type="pmid">19788360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elston</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Thaker</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Immune reconstitution inflammatory syndrome.</article-title>
            <source>Int J STD AIDS</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>221</fpage>
            <page-range>221-4</page-range>
            <pub-id pub-id-type="pmid">19304962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tappuni</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Immune reconstitution inflammatory syndrome.</article-title>
            <source>Adv Dent Res</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-6</page-range>
            <pub-id pub-id-type="pmid">21441488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boulougoura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sereti</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>HIV infection and immune activation: the role of coinfections.</article-title>
            <source>Curr Opin HIV AIDS</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>191</fpage>
            <page-range>191-200</page-range>
            <pub-id pub-id-type="pmid">26720550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meintjes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scriven</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marais</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management of the immune reconstitution inflammatory syndrome.</article-title>
            <source>Curr HIV/AIDS Rep</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-50</page-range>
            <pub-id pub-id-type="pmid">22752438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beatty</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Immune reconstitution inflammatory syndrome.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2010</year>
            <month>May</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>393</fpage>
            <page-range>393-407, Table of Contents</page-range>
            <pub-id pub-id-type="pmid">20413021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22932.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meintjes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thienemann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schutz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Buyze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ravinetto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Loen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colebunders</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maartens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lynen</surname>
                <given-names>L</given-names>
              </name>
              <collab>PredART Trial Team</collab>
            </person-group>
            <article-title>Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>15</day>
            <volume>379</volume>
            <issue>20</issue>
            <fpage>1915</fpage>
            <page-range>1915-1925</page-range>
            <pub-id pub-id-type="pmid">30428290</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
